This study, called INTERLIVER, is looking at liver transplant biopsies to improve how doctors diagnose problems like rejection. Researchers will use a small piece of a liver biopsy (about 5 mm) that you would already be getting for your medical care. They will use a new diagnostic system called the Molecular Microscope® Diagnostic System (MMDx) to analyze the biopsy's molecular features, along with standard biopsy results and your clinical information. The goal is to develop more accurate ways to identify T cell mediated rejection and antibody mediated rejection in liver transplants. You can join if you are 18 or older and are having a liver biopsy for clinical reasons. Pregnant women cannot participate. The study is currently unclear on its recruitment status.

Study design

This is an observational study planning to include 300 participants. It is not a treatment study, but rather looks at information from existing medical procedures.

What's involved

You would have a small piece of a liver biopsy, already scheduled for your medical care, used for gene expression study. No additional procedures are required.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is to assign molecular scores within a reference set of 100 biopsies, measured at two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.